[Protective effect of rupatadine against oleic acid-induced acute lung injury in rabbits].
Acute lung injury (ALI) makes up a spectrum of disease that is commonly defined as "acute non-cardiogenic edematous lung injury". It may contribute to morbidity and mortality in the critically ill patient in the intensive care unit. ALI was induced by oleic acid in rabbits. During the experiment, blood samples were taken from cervical artery and subjected to blood-gas analysis at different time points after oleic acid injection. Shortly after the rabbits were killed at 3 hour after iv OA injection, bronchoalveolar lavage fluid (BALF) was colleted, and the concentrations of protein, platelet-activating factor (PAF), intercellular adhesion molecule-1 (ICAM-1), interleukin 8 (IL-8) in BALF were then measured by ELISA. The ratio of wet to dry weight (W/D) of left lung was calculated to assess alveolar edema. Lung tissue was fixed in formaldehyde and stained with HE, and examined under a light microscope. The OA-induced elevation of arterial blood oxygen pressure was inhibited, as well as PAF, ICAM-1, IL-8 in BALF in rupatadine group. Furthermore, rupatadine also decreased the concentration of protein in BALF and inhibited the increase of the W/D weight ratio significantly. Light microscopic findings showed that the damage in rupatadine groups was far less severe than that in OA model group. Pretreatment with rupatadine has a beneficial effect on acute lung injury induced by oleic acid in rabbits. The ultimate reduction of inflammatory factors was involved, at least in part, in the mechanism of action of rupatadine effects.
Zhang
Lin-Li
LL
Center of New Drug Research and Development, Jiangsu Province Key Laboratory for Molecular and Medical Biotechnology, College of Life Science, Nanjing Normal University, Nanjing 210097, China.
Lu
Jing
J
Yu
Shu-Qin
SQ
He
Jian-Lin
JL
Zhou
Min
M
Xu
Guang-Lin
GL
D000818:Animals; D001784:Blood Gas Analysis; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry; D003533:Cyproheptadine / Q000031:analogs & derivatives* / Q000494:pharmacology; D004797:Enzyme-Linked Immunosorbent Assay; D018799:Intercellular Adhesion Molecule-1 / Q000378:metabolism; D016209:Interleukin-8 / Q000378:metabolism; D008168:Lung / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D008297:Male; D019301:Oleic Acid; D010972:Platelet Activating Factor / Q000378:metabolism; D020011:Protective Agents / Q000494:pharmacology*; D011817:Rabbits; D011897:Random Allocation; D012128:Respiratory Distress Syndrome / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control*
D016209:Interleukin-8; D010972:Platelet Activating Factor; D020011:Protective Agents; D018799:Intercellular Adhesion Molecule-1; C103639:rupatadine; D019301:Oleic Acid; D003533:Cyproheptadine